Ryan Martin, MD
Pulmonary Disease · Lincoln, NENPI 1790981082
Payments from drug & device makers
Across 742 payments — averaging $808.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$547K
- Sanofi$27K
- Intuitive Surgical$19K
- GSK$4K
- Veran Medical Technologies, Inc.$798
- Jazz Pharmaceuticals Inc.$282
- plus $2K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 503 | $546,892 |
| Sanofi | 33 | $27,222 |
| Intuitive Surgical | 35 | $18,730 |
| GSK | 49 | $4,447 |
| Veran Medical Technologies, Inc. | 6 | $798 |
| Jazz Pharmaceuticals Inc. | 17 | $282 |
| Grifols USA, LLC | 12 | $266 |
| Sunovion Pharmaceuticals Inc. | 14 | $246 |
| Amgen | 9 | $156 |
| Regeneron Healthcare Solutions, Inc. | 7 | $107 |
| Harmony Biosciences LLC | 5 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $92 |
| Inspire Medical Systems, Inc. | 1 | $87 |
| Boehringer Ingelheim | 6 | $86 |
| United Therapeutics Corporation | 4 | $68 |
| Verona Pharma, Inc. | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $52 |
| Insmed, Inc. | 3 | $49 |
| Resmed Corp | 1 | $48 |
| Boston Scientific | 3 | $43 |
| Pulmonx Corporation | 1 | $40 |
| Tactile Systems Technology Inc | 1 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $29 |
| Merck | 2 | $29 |
| Philips North America LLC | 2 | $27 |
| Novartis | 2 | $27 |
| Baxter Healthcare | 1 | $26 |
| Electromed, Inc. | 3 | $24 |
| Circassia Inc. | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Liquidia Technologies, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| AbbVie | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Ambu Inc. | 1 | $6 |
How this compares
$600,260 in reported general payments places this provider in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Lincoln
- Radu NeamuLincoln$469K
- Kevin ReichmuthLincoln$191K
- John TrappLincoln$34K
- William JohnsonLincoln$30K
- Douglas FiedlerLincoln$23K
- Harvey HopkinsLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.